You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Mallinckrodt
Harvard Business School
Baxter

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 7,592,161

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,592,161
Title:Methods for analyzing the insertion capabilities of modified group II introns
Abstract: The present invention provides a system and methods for analyzing the function of nucleotide integrases and modified group II introns. The system comprises a donor plasmid comprising a wild-type or modified group II intron, a recipient plasmid comprising a DNA recognition site and a promoterless reporter gene downstream of the DNA target site, and a host cell. The method comprises the steps of transforming a host cell with the donor and recipient plasmids, assaying for expression of the reporter gene, isolating plasmid DNA from the cotransformed cells, and analyzing the plasmid DNA to confirm that the group II intron has been inserted into the target sequence. The present invention also provides a method for simultaneously analyzing the activity of two or more modified nucleotide integrases. The present invention also relates to methods of preparing a library of donor plasmids containing a plurality of diverse modified group II intron DNA sequences.
Inventor(s): Lambowitz; Alan M. (Austin, TX), Guo; Huatao (Alhambra, CA), Karberg; Michael (Austin, TX)
Assignee: The Ohio State University Research Foundation (Columbus, OH) The University of Texas Board of Regents of the University of Texas System (Austin, TX)
Application Number:10/277,643
Patent Claims:see list of patent claims

Details for Patent 7,592,161

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Ohio State University Research Foundation (Columbus, OH) The University of Texas Board of Regents of the University of Texas System (Austin, TX) 2019-10-15 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Ohio State University Research Foundation (Columbus, OH) The University of Texas Board of Regents of the University of Texas System (Austin, TX) 2019-10-15 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Ohio State University Research Foundation (Columbus, OH) The University of Texas Board of Regents of the University of Texas System (Austin, TX) 2019-10-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Harvard Business School
AstraZeneca
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.